Abstract
With the arrival of effective symptomatic treatments and the promise of drugs that may delay progression, we now need to identify Alzheimer’s disease (AD) at an early stage of the disease. To diagnose AD earlier and more accurately, attention has been directed toward peripheral biochemical markers. This article reviews promising potential cerebrospinal fluid (CSF) biomarkers for AD focussing on their role in clinical diagnosis. In particular, two biochemical markers, CSF total tau (t-tau) protein and the 42 amino acid form of β-amyloid (Aβ42), perform satisfactorily enough to achieve a role in the clinical diagnostic settings of patients with dementia together with the cumulative information from basic clinical work-up, genetic screening, and brain imaging. These CSF markers are particularly useful to discriminate early or incipient AD from age-associated memory impairment, depression, and some secondary dementias. In order to discriminate AD from other primary dementia disorders, however, more accurate and specific markers are needed. Preliminary evidence strongly suggests that quantification of tau phosphorylated at specific sites in CSF improves early detection, differential diagnosis, and tracking of disease progression in AD.
Similar content being viewed by others
References
Mckhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34, 939–944.
Tierney M. C., Fisher R. H., Lewis A. J., et al. (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology 38, 359–364.
Jellinger K. A. (1996) Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol. 91, 219–220.
Galasko D., Hansen L. A., Katzman R., Wiederholt W., Masliah E., Terry R., et al. (1994) Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch. Neurol. 51, 888–895.
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. (1998) Consensus report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease.” Neurobiol. Aging 19, 109–116.
Goedert M. (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. TINS 16, 460–465.
Vandermeeren M., Mercken M., Vanmechelen E., Six J., Van de Voorde A., Martin J. J., Cras P. (1993) Detection of τ proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828–1834.
Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., Vanmechelen E. (1995) Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol. Chem. Neuropathol. 26, 231–245.
Vigo-Pelfrey C., Seubert P., Barbour R., Blomquist C., Lee M., Lee D., et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 45, 788–793.
Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., et al. (1999) Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 52, 1555–1562.
Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., et al. (1998) Cernrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community-based follow-up study. J. Neurol. Neurosurg. Psychiatry 64, 298–305.
Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., et al. (1998) Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer’s disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 20, 227–235.
Skoog I., Vanmechelen E., Andreasson L. A., Palmertz B., Davidsson P., Hesse C., and Blennow K. (1995) A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4, 433–442.
Arai H., Satoh-Nakagawa T., Higuchi M., Morikawa Y., Miura M., Kawakami H., et al. (1998) No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci. Lett. 256, 174–176.
Mecocci P., Cherubini A., Bregnocchi M., Chionne F., Cecchetti R., Lowenthal D. T., and Senin U. (1998) Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis. Assoc. Disord. 12, 211–214.
Arai H., Higuchi S., and Sasaki H. (1997) Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer’s disease. Gerontology 43(Suppl. 1), 2–10.
Green A. J., Harvey R. J., Thompson E. J., and Rossor M. N. (1999) Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s disease. Neurosci. Lett. 259, 133–135.
Molina L., Touchon J., Herpe M., Lefranc D., Duplan L., Cristol J. P., et al. (1999) Tau and apo E in CSF: potential aid for discriminating Alzheimer’s disease from other dementias. Neuroreport 10, 3491–3495.
Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C. M., Miura M., et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Comm. 236, 262–264.
Higuchi M., Tashiro M., Arai H., Okamura N., Hara S., Higuchi S., et al. (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp. Neurol. 162, 247–256.
Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., et al. (1995) Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol. 38, 643–648.
Sjögren M., Minthon L., Davidsson P., Granérus A. K., Clarberg A., Vanderstichele H., et al. (2000) CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Transm. 107, 563–579.
Kanemaru K., Kameda N., and Yamanouchi H. (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 54, 1875–1876.
Kudo T., Mima T., Hashimoto R., Nakao K., Morihara T., Tanimukai H., et al. (2000) Tau protein is a potential biological marker for normal pressure hydrocephalus. Psych. Clin. Neurosci. 54, 199–202.
Mitani K., Furiya Y., Uchihara T., Ishii K., Yamanouchi H., Mizusawa H., and Mori H. (1998) Increased CSF tau protein in corticobasal degeneration. J. Neurol. 245, 44–46.
Morikawa Y., Arai H., Matsushita S., Kato M., Higuchi S., Miura M., et al. (1999) Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin. Exp. Res. 23, 575–577.
Urakami K., Mori M., Wada K., Kowa H., Takeshima T., Arai H., et al. (1999) A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci. Lett. 259, 127–129.
Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., and Blennow K. (2000) Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischaemic stroke. J. Alzheimer Dis. 2, 199–206.
Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., et al. (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225, 210–212.
Van Everbroeck B., Green A. J. E., Phals P., Martins J. J., and Cras P. (1999) Decreased levels of amyloid β 1–42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J. Alzheimer Dis. 1, 419–424.
Emery V. O. and Oxman T. E. (1992) Update on the dementia spectrum of depression. Am. J. Psychiatry 149, 305–317.
Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., et al. (1999) Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample. Neurology 53, 1488–1494.
Buerger nee Buch K., Padberg F., Nolde T., Teipel S. J., Stubner S., Haslinger A., et al. (1999) Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer’s disease compared with controls. Neurosci. Lett. 277, 21–24.
Buerger K., Zinkowski R., Teipel S. J., Tapiola T., Arai H., Blennow K., et al. CSF tau protein phosphorylated arthreonine 231 in the differential diagnosis of Alzheimer’s disease. Submitted, 2001.
Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., and Blennow K. (2001) Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci. Lett. 297, 187–190.
Hampel H., Buerger K., Kohnken R., Teipel S. J., Zinkowski R., Moeller H. J., et al. (2001) Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49, 545–546.
Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., et al. (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann. Neurol. 45, 504–511.
Andreasen N., Hesse C., Davidsson P., Wallin A., Minthon L., Winblad B., et al. (1999) Cerebrospinal fluid β-amyloid(1-42) in Alzheimer’s disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673–680.
Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. (2001) Evaluation of CSF t-tau and CSF-Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch. Neurol. 58, 373–379.
Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., Schroter A., Ratzka P., et al. (2000) Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54, 1099–1102.
Sjögren M., Gisslén M., Vanmechelen E., and Blennow K. (2001) Low cerebrosinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 314, 33–36.
Folstein M., Folstein S., and McHugh P. (1975) “Mini-Mental State” A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198.
Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., and Kokmen E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308.
Arai H., Nakagawa T., Kosaka Y., Higuchi M., Matsui T., Okamura N., et al. (1997) Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer’s Res. 3, 211–213.
Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Longitudinal studies of cerebrospinal fluid biochemistry in patients with mild cognitive impairment. Submitted, 2001.
Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., et al. (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166, 201–203.
Blennow K., Wallin A., and Häger O. (1993) Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88, 221–223.
Kosunen O., Soininen H., Paljärvi L., Heinonen O., Talasniemi S., and Riekkinen P. J., Sr. (1996) Diagnostic accuracy of Alzheimer’s disease: a neuropathological study. Acta Neuropathol. 91, 185–193.
Tomlinson B. E. and Henderson G. (1976) Some quantitative cerebral findings in normal and emented old people, in Neurobiology of Aging (Terry R. D. and Gershon S., eds.), Raven Press, New York, NY, pp. 183–204.
Davies L., Wolska B., Hilbich C., et al. (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease. Neurology 38, 1688–1693.
Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann. Neurol. 45, 358–368.
Kahle P. J., Jakowec M., Teipel S. J., Hampel H., Petzinger G. M., Di Monte D. A., et al. (2000) Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 54, 1498–1504.
Hampel H., Teipel S. J., Padberg F., Haslinger A., Riemenschneider M., Schwarz M. J., et al. (1999) Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res. 823, 104–112.
Jensen M., Basun H., and Lannfelt L. (1995) Increased cerebrospinal fluid tau in patients with Alzheimer’s disease. Neurosci. Lett. 186, 189–191.
Riemenschneider M., Buch K., Schmolke M., Kurz A., and Guder W. G. (1996) Cerebrospinal protein tau is elevated in early Alzheimer’s disease. Neurosci. Lett. 212, 209–211.
Rösler N., Wichart I., and Jellinger K. A. (1996) Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 60, 237–238.
Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., et al. (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta 1-40, and A beta 1-42(43) in Alzheimer’s disease: a study in Japan. Ann. Neurol. 44, 17–26.
Kurz A., Riemenschneider M., Buch K., Willoch F., Bartenstein P., Muller U., and Guder W. (1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12, 372–377.
Tapiola T., Lehtovirta M., Ramberg J., Helisalmi S., Linnaranta K., Riekkinen P Sr., and Soininen H. (1998) CSF tau is related to apolipoprotein E genotype in early Alzheimer’s disease. Neurology 50, 169–174.
Vanderstichele H., Blennow K., D’Heuvaert N. D., Buyse M. A., Wallin A., Andreasen N., et al. (1998) Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF in Progress in Alzheimer’s and Parkinson’s Diseases (Fisher A., Hanin I., and Yoshida M., eds.), Plenum Press, New York, NY, pp. 773–778.
Ishiguro K., Ohno H., Arai H., Yamaguchi H., Urakami K., Park J. M., et al. (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci. Lett. 270, 91–94.
Sjögren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelsö C., et al. Both total and hyperphosphorylated tau are increased in Alzeimer’s disease. J. Neurol. Neurosurg. Psychiatry 70, 624–630.
Munroe W. A., Southwick P. C., Chang L., Scharre D. W., Echols C. L. Jr., Fu P. C., Whaley J. M., Wolfert R. L. (1995) Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. Ann. Clin. Lab. Sci. 25, 207–217.
Galasko D., Clark C., Chang L., Miller B., Green R. C., Motter R., Seubert P. (1997) Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 48, 632–635.
Galasko D., Chang L., Motter R., Clark C. M., Kaye J., Knopman D., et al. (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55, 937–945.
Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., et al. (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 186, 181–183.
Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., et al. (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 287, 187–190.
Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van der Perre B., Sjögren M., et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49–52.
Riemenschneider M., Schmolke M., Lautenschlager N., Guder W. G., Vanderstichele H., Vanmechelen E., and Kurz A. (2000) Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284, 85–88.
Tamaoka A., Sawamura N., Fukushima T., Shoji S., Matsubara E., Shoji M., et al. (1997) Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Sci. 148, 41–45.
Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., et al. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22,908–22,914.
Mehta P.D., Pirttilä T., Mehta S. P., Sersen E. A., Aisen P. S., and Wisniewski H. M. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57, 100–105.
Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., and Blennow K. (1999c) CSF t-tau and CSF-Aβ42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neurosci. Lett. 273, 5–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blennow, K., Vanmechelen, E. & Hampel, H. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol 24, 87–97 (2001). https://doi.org/10.1385/MN:24:1-3:087
Issue Date:
DOI: https://doi.org/10.1385/MN:24:1-3:087